Songjiang Ma Biography and Net Worth

President of Gyre Therapeutics

Mr. Songjiang Ma is Gyre Therapeutics’ President and board member. He has more than 27 years of experience in the pharmaceutical industry.

Prior to joining Gyre, Mr. Ma founded Kangdini Factory, one of Beijing Continent’s (BC) founding Shareholders in June 1996, and acted as its general manager from June 1996 to March 2006, and then as the supervisor since March 2006. After the incorporation of BC in June 2002, he served as the vice president of BC from June 2002 to July 2011, and then as general manager from July 2011 to April 2023 responsible for the overall management and operation of the company. Mr. Ma has been a director of BC since June 2006 and was elected honorary chairman in April 2023. Prior to founding Kangdini Factory, Mr. Ma served as the general manager of Beijing Pan-continental Medical Limited.

What is Songjiang Ma's net worth?: The estimated net worth of Songjiang Ma is at least $25.98 million as of March 19th, 2025. Mr. Ma owns 2,827,018 shares of Gyre Therapeutics stock worth more than $25,980,295 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Ma may own. Learn More about Songjiang Ma's net worth.
How do I contact Songjiang Ma?: The corporate mailing address for Mr. Ma and other Gyre Therapeutics executives is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. Gyre Therapeutics can also be reached via phone at (619) 949-3681 and via email at investors@catbio.com. Learn More on Songjiang Ma's contact information.
Has Songjiang Ma been buying or selling shares of Gyre Therapeutics?: Songjiang Ma has not been actively trading shares of Gyre Therapeutics during the last quarter. Most recently, Songjiang Ma sold 2,000 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $10.13, for a transaction totalling $20,260.00. Following the completion of the sale, the president now directly owns 2,827,018 shares of the company's stock, valued at $28,637,692.34. Learn More on Songjiang Ma's trading history.
Who are Gyre Therapeutics' active insiders?: Gyre Therapeutics' insider roster includes Songjiang Ma (President), and Nassim Usman (Director). Learn More on Gyre Therapeutics' active insiders.
Are insiders buying or selling shares of Gyre Therapeutics?: During the last year, insiders at the sold shares 25 times. They sold a total of 65,506 shares worth more than $799,621.30. The most recent insider tranaction occured on March, 19th when President Songjiang Ma sold 2,000 shares worth more than $20,260.00. Insiders at Gyre Therapeutics own 19.5% of the company. Learn More about insider trades at Gyre Therapeutics.
Information on this page was last updated on 3/19/2025.

Songjiang Ma Insider Trading History at Gyre Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2025	Sell	2,000	$10.13	$20,260.00	2,827,018
3/17/2025	Sell	2,000	$12.09	$24,180.00	2,829,260
3/14/2025	Sell	2,000	$12.31	$24,620.00	2,831,260
3/12/2025	Sell	2,000	$11.74	$23,480.00	2,835,260
3/10/2025	Sell	2,000	$10.14	$20,280.00	2,839,260
3/7/2025	Sell	2,000	$10.25	$20,500.00	2,841,260
2/10/2025	Sell	2,000	$11.90	$23,800.00	2,877,138
2/4/2025	Sell	2,000	$11.62	$23,240.00	2,885,138
1/29/2025	Sell	2,000	$11.43	$22,860.00	2,893,138
1/27/2025	Sell	2,000	$11.18	$22,360.00	2,897,138
1/23/2025	Sell	2,000	$10.49	$20,980.00	2,901,138
1/21/2025	Sell	2,000	$10.85	$21,700.00	2,905,138
1/17/2025	Sell	2,000	$10.72	$21,440.00	2,907,138
1/15/2025	Sell	2,000	$10.85	$21,700.00	2,911,138
1/13/2025	Sell	56	$10.10	$565.60	2,915,138
1/10/2025	Sell	1,057	$10.02	$10,591.14	2,915,194
1/6/2025	Sell	941	$10.16	$9,560.56	2,917,526
1/2/2025	Sell	2,000	$12.40	$24,800.00	2,920,467
12/30/2024	Sell	2,000	$12.50	$25,000.00	2,924,467
12/26/2024	Sell	2,000	$12.70	$25,400.00	2,928,467
12/23/2024	Sell	2,000	$12.27	$24,540.00	2,932,467
12/19/2024	Sell	2,000	$10.82	$21,640.00	2,936,467
12/17/2024	Sell	2,000	$11.05	$22,100.00	2,940,467
1/3/2024	Sell	833	$11.85	$9,871.05	2,918,467

See Full Table

Songjiang Ma Buying and Selling Activity at Gyre Therapeutics

Gyre Therapeutics Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Today's Range

Now: $9.19

$8.93

$9.48

50 Day Range

MA: $9.63

$6.41

$12.62

2 Week Range

Now: $9.19

$6.11

$19.00

Volume

105,491 shs

Average Volume

92,662 shs

Market Capitalization

$860.29 million

P/E Ratio

183.80

Dividend Yield

N/A

Beta

2.03